Identification

Name
Polyethylene glycol 400
Accession Number
DB11077
Type
Small Molecule
Groups
Approved
Description

Polyethylene glycols (PEGs) are products made of condensed ethylene oxide and water that can contain various derivatives and have various functions. Because many PEG types are hydrophilic, they are favorably used as enhancers of penetration, and used heavily in topical dermatological preparations. PEGs, along with their many nonionic derivatives, are widely utilized in cosmetic products as surfactants, emulsifiers, cleansing agents, humectants, and skin conditioners [9].

Polyethylene glycol 400 (PEG 400) is a low-molecular-weight grade of polyethylene glycol with a low-level toxicity. It is very hydrophilic, which renders it a useful ingredient in drug formulations to augment the solubility and bioavailability of weakly water-soluble drugs. It is used in ophthalmic solutions for the relief of burning, irritation and/or discomfort that follows dryness of the eye [7]. PEG "400" indicates that the average molecular weight of the specific PEG is 400 [10].

PEGylation occurs when PEGs are attached to numerous protein medications, allowing for greater solubility for selected drugs. Examples of PEGylated medications are PEG-interferon alpha (Pegintron) and PEG-filgrastim. In addition, PEG is available as a bowel preparation for colonoscopy procedures and as a laxative [10].

Synonyms
Not Available
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Blink Gel TearsSolution / drops2.5 mg/1mLOphthalmicAmo Hangzhou Co., Ltd2008-05-01Not applicableUs
Blink TearsSolution / drops2.5 mg/1mLOphthalmicAmo Hangzhou Co., Ltd2008-02-01Not applicableUs
Blink TearsSolution / drops2.5 mg/1mLOphthalmicAbbott Medical Optics Inc.2008-03-172017-08-31Us
Blink TearsSolution / drops2.5 mg/1mLOphthalmicAbbott Medical Optics Inc.2016-03-15Not applicableUs
Dark Spot CorrectorCream.3 mg/15mgTopicalLange SAS2012-09-17Not applicableUs
Lightening Day CreamCream2.5 mg/50mgTopicalLange SAS2012-07-18Not applicableUs
Visine True Tears - LiquidLiquid1 %OphthalmicPfizer Canada Inc., Consumer Healthcare Division1996-12-312003-07-30Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Advance Relief Eye DropsPolyethylene glycol 400 (1000 mg/100mL) + Dextran 70 (100 mg/100mL) + Povidone (1000 mg/100mL) + Tetrahydrozoline hydrochloride (50 mg/100mL)Solution / dropsOphthalmicWinCo Foods, LLC2015-01-09Not applicableUs
Advanced reliefPolyethylene glycol 400 (10 mg/1mL) + Dextran 70 (1 mg/1mL) + Povidone (10 mg/1mL) + Tetrahydrozoline hydrochloride (0.5 mg/1mL)LiquidOphthalmicAmerican Sales Company2011-09-07Not applicableUs
Advanced reliefPolyethylene glycol 400 (10 mg/1mL) + Dextran 70 (1 mg/1mL) + Povidone (10 mg/1mL) + Tetrahydrozoline hydrochloride (0.5 mg/1mL)LiquidOphthalmicKareway Product, Inc.2011-08-11Not applicableUs
Advanced reliefPolyethylene glycol 400 (10 mg/1mL) + Dextran 70 (1 mg/1mL) + Povidone (10 mg/1mL) + Tetrahydrozoline hydrochloride (0.5 mg/1mL)LiquidOphthalmicSamchundang Pharm. Co., Ltd.2010-08-29Not applicableUs
Advanced Relief Eye DropsPolyethylene glycol 400 (1 %) + Dextran 70 (0.1 %) + Povidone (1 %) + Tetrahydrozoline hydrochloride (0.05 %)SolutionOphthalmicTeva2010-08-30Not applicableCanada
Advanced Relief Eye DropsPolyethylene glycol 400 (1 %) + Dextran 70 (0.1 %) + Povidone (1 %) + Tetrahydrozoline hydrochloride (0.05 %)SolutionOphthalmicKc Pharmaceuticals, Inc.Not applicableNot applicableCanada
Artificial TearsPolyethylene glycol 400 (10 mg/1mL) + Glycerin (2 mg/1mL) + Hypromellose (2 mg/1mL)LiquidOphthalmicAmerican Sales Company2010-09-06Not applicableUs
Assured Advanced Relief EyePolyethylene glycol 400 (10 mg/1mL) + Dextran 70 (1 mg/1mL) + Povidone (10 mg/1mL) + Tetrahydrozoline hydrochloride (0.5 mg/1mL)SolutionOphthalmicGreenbrier International, Inc.2013-02-28Not applicableUs
CAREALL Artifical TearsPolyethylene glycol 400 (10 mg/1mL) + Glycerin (2 mg/1mL) + Hypromellose (2 mg/1mL)Solution / dropsOphthalmicNew World Imports, Inc2014-01-01Not applicableUs
CareOne LubricantPolyethylene glycol 400 (4 mg/1mL) + Propylene glycol (3 mg/1mL)Solution / dropsOphthalmicFOODHOLD U.S.A., LLC2017-05-18Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
PegPolyethylene glycol 400 (45 g/100g) + Polyethylene glycol (55 g/100g)CreamTopicalBiocellerex, Inc.2015-07-142016-01-05Us
International/Other Brands
Advanced Relief / Blink Tears / Colirio Ocusan / CV single use lubricant eye drops / GNP Lubricant Eye / Good Neighbour Pharmacy Lubricant Eye Drops / Good Sense Lubricant Eye Drops / Leader Lubricant Eye Drops / Meijer Lubricant Eye / QC ultra lubricant eye / Tears Lubricant
Categories
UNII
B697894SGQ
CAS number
25322-68-3
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

PEG-400 has been indicated for the temporary relief of burning and irritation due to dryness of the eye, and for protection against further irritation and desiccation [14], [15], [16].

Pharmacodynamics

PEG, when used as PEG-400 for eye lubrication provides relief of dry eye symptoms and prevents further irritation, thus protecting the eye from injury [15]. PEG allows comfortable eye drop/natural tear instillation by offering improved spreading of the drop over the ocular surface with diminished blurring [14, 15].

Mechanism of action

PEG, depending on molecular weight, has various mechanisms of action [4], [5], [6], [7]. For the purpose of Peg-400, the mechanism of action on the eye tissues will be the primary focus of discussion.

PEG-400 is considered a lacrimomimetic, or a synthetic ocular lubricant that improves one or more components of the lacrimal film by augmenting the tear volume and stability and by protecting the eye surface against desiccation [16]. Hydroxypropyl-guar (HPG) is used along with polyethylene glycol 400 (PEG) and propylene glycol (PG) as a gelling agent that conforms to abnormalities of the tear film and existing irregularities on the ocular surface [16].

PEG provides lubrication and acts as a surfactant by coating the eye and interacting with propylene glycol and other solutions that help to act as surfactants on the eye mucosa [15]. This allows for long-lasting, soothing effects [15].

Recent studies involving nanoparticle drug delivery have demonstrated that PEG can achieve sustained drug delivery. The delivery of drugs to mucosal surfaces is a significant challenge due to the presence of the protective mucus layer that acts to trap and quickly remove foreign particles. Nanoparticles designed to rapidly cross mucosal barriers (mucus-penetrating particles, “MPP”) have proven promising for augmenting drug distribution, and efficacy at various mucosal surfaces. Mucus- penetrating particles are heavily coated with polyethylene glycol (PEG), protecting the nanoparticle core from adhesion with mucus [17].

Polyethylene glycol, when free in solution, may also demonstrate attraction to the surfaces of various types of vesicles, cells or macromolecules, leading to polymer adsorption and subsequently either a repulsion or to an attraction, via bridging, of the surfaces or vesicles—again strongly depending on the temperature, molecular weight, and concentration of the polyethylene glycol. Low molecular weight polyethylene glycol (such as PEG-400) generally promotes cells or vesicles to adhere (depletion attraction), high molecular weight polyethylene glycol causes them to repel [18].

TargetActionsOrganism
UEctonucleotide pyrophosphatase/phosphodiesterase family member 1
other
Human
Absorption

PEG has low toxicity profile with an absorption of less than 0.5% [10].

Topical absorption of PEG occurs and, demonstrates a molecular weight dependence similar to that of PEG given orally. Absorption by this route is likely to be poor [12].

Volume of distribution
Not Available
Protein binding

Despite that fact that PEG is believed to be an excellent material to resist protein adsorption, there is a lack of quantitative evidence regarding interactions between proteins and PEG. A study has been performed that suggests that a large number of PEG molecules could associate with protein molecules [3].

Metabolism

The metabolism of PEG involves the oxidation of the alcohol groups located on the PEG to a carboxylic acid. For example, the diacid and hydroxyl acid metabolites of PEG have been measured in the plasma and urine of burn patients and rabbits and in the bile of cats. In the isolated guinea pig liver and in rat/guinea pig in vitro, PEG has demonstrated to be sulfated. Evidence from experiments with PEG400 suggests that ethylene glycol is not formed as a metabolite of PEG in humans. Negligible amounts of oxalic acid are liberated after the metabolism of PEG [12].

The first phase of metabolism of PEG in mammals is regulated by the enzyme alcohol dehydrogenase. Liver cytochorome P450 enzymes may also play a role in the oxidation of PEG, although the evidence for this is not clear [12]. Also, PEG has been shown to be metabolized by sulfotransferase enzymes. Although there is evidence that PEG can be metabolized to various phase 1 and phase 2 metabolites, the toxicology data presented above indicate that these metabolites are of very little toxicological concern. However, metabolism of PEG to the acid metabolite(s) has been implicated in the acidosis and hypercalcemia observed in patients after overdose [12]. It is clear that these metabolites can be formed in multiple toxicology species and that the phase 1 metabolites are seen in animals and humans. These data indicate that humans and animals will be exposed to similar metabolites after administration of PEG [12]. metabolic clearance of PEG decreases markedly as molecular weight increases. For PEG400, up to 25% of the dose may be metabolized in humans (Schaffer et al., 1950); similar results are also seen in the rabbit [12].

The absorption of PEG by the oral route is molecular weight- dependent. Urinary recovery data for PEG400 indicate that 50 to 60% of PEG with this molecular weight is absorbed from the intestine [12]. In the case of PEG-400, up to 25% of the dose may be metabolized in humans. Similar results have also been obtained in studies on the rabbit [12].

Route of elimination

Human excretion studies have demonstrated that 86% and 96% of PEG1000 and 6000 were excreted in the urine 12 h after intravenous administration. Specific data on PEG-400 are not available [12]. In rats, urine PEG undergoes biliary excretion, and this process is depending on molecular weight, with hepatic clearance reaching a minimum at about 50 kDa molecular mass (in mouse)[12].

Half life

Great than 24h [11].

Clearance

In mice, lease than <10 % of the administered dose was cleared by the liver [12].

Toxicity

PEG of different molecular weights by a range of routes has been studied extensively, and has not led to any major toxicities, and signs/symptoms of toxicity that do occur are only observed at a much higher than therapeutic dose [12].

LD50 = 157000 mg/kg, intragastric, guinea pigs [MSDS] LD50 = 28915 mg/kg, intragastric, mice, rats [MSDS] LD50 = 9708 mg/kg, intra-abdominal, rats [MSDS] LD50= 7312 mg/kg, intravenous, rats [MSDS]

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
Abicipar PegolThe therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Polyethylene glycol 400.
AcarboseAcarbose may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
AcrivastineAcrivastine may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
Food Interactions
Not Available

References

General References
  1. Basit AW, Newton JM, Short MD, Waddington WA, Ell PJ, Lacey LF: The effect of polyethylene glycol 400 on gastrointestinal transit: implications for the formulation of poorly-water soluble drugs. Pharm Res. 2001 Aug;18(8):1146-50. [PubMed:11587486]
  2. Foulks GN: Clinical evaluation of the efficacy of PEG/PG lubricant eye drops with gelling agent (HP-Guar) for the relief of the signs and symptoms of dry eye disease: a review. Drugs Today (Barc). 2007 Dec;43(12):887-96. doi: 10.1358/dot.2007.43.12.1162080. [PubMed:18174974]
  3. Wu J, Wang Z, Lin W, Chen S: Investigation of the interaction between poly(ethylene glycol) and protein molecules using low field nuclear magnetic resonance. Acta Biomater. 2013 May;9(5):6414-20. doi: 10.1016/j.actbio.2013.01.006. Epub 2013 Jan 11. [PubMed:23318816]
  4. Polyethylene glyco [Link]
  5. SIGMA-ALDRICH PEG 400 [Link]
  6. Polyethylene glycol 400 (PEG400) affects the systemic exposure of oral drugs based on multiple mechanisms: taking berberine as an example [Link]
  7. Polyethylene glycol [Link]
  8. Polyethylene Glycol [Link]
  9. Safety Evaluation of Polyethylene Glycol (PEG) Compounds for Cosmetic Use [Link]
  10. PEG-400 [Link]
  11. Safety of Total Daily Doses of Polyethylene Glycol (PEG) 400 Administered Orally to Healthy Male Human Subjects [Link]
  12. PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies [Link]
  13. The Absorption and Excretion of a Liquid Polyethylene Glycol [Link]
  14. Polyethylene Glycol 400 [Link]
  15. Systane Mechanism of Action [Link]
  16. Ocular lubricants: what is the best choice? [Link]
  17. Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex vivo and Distribution in vivo [Link]
  18. The different faces of poly(ethylene glycol) [Link]
External Links
PubChem Substance
347911107
AHFS Codes
  • 52:92.00 — EENT Drugs, Miscellaneous
MSDS
Download (229 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingSupportive CareDiverticulitis / Inflammatory Bowel Diseases (IBD) / Neoplasms, Colorectal / Surgical Site Infections1
1CompletedTreatmentDry Eye Syndrome (DES)1
1CompletedTreatmentDry Eye Syndromes / Lubricant Allergy / Tear Disorder1
1RecruitingTreatmentMenopause / Painful Intercourse / Sexual Dysfunctions1
1RecruitingTreatmentPeripheral Nerve Injury (PNI)1
1, 2CompletedPreventionGeneral Surgery1
1, 2CompletedTreatmentHepatitis C Viral Infection1
1, 2CompletedTreatmentHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV)1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection3
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Hepatitis C Viral Infection1
2CompletedTreatmentConjunctivitis, Seasonal Allergic1
2CompletedTreatmentEye Dryness1
2CompletedTreatmentHepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHepatitis C Viral Infection2
2CompletedTreatmentHepatitis C Viral Infection / Pain, Chronic1
2CompletedTreatmentHepatitis C Virus (HCV) Infection2
2CompletedTreatmentHepatitis C Virus (HCV) Infection / Liver Cirrhosis, Experimental1
2CompletedTreatmentMacular Edema (ME) / Retinopathy, Diabetic1
2RecruitingTreatmentThyroid Eye Disease1
2TerminatedTreatmentChronic Hepatitis C Virus (HCV) Infection1
2TerminatedTreatmentDry Eye Syndromes1
2WithdrawnTreatmentLacrimation increased1
2, 3CompletedTreatmentColonoscopy1
2, 3CompletedTreatmentConjunctivitis, Viral1
2, 3RecruitingTreatmentClostridium Difficile1
3CompletedDiagnosticColon Capsule Completion Rates / Colon Capsule Polyp Detection / Quality of Bowel Preparation for the Colon Capsule1
3CompletedOtherBowel Cleansing Efficacy / Unrecognized Condition1
3CompletedTreatmentChronic HCV Infection1
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection4
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Hepatitis C Viral Infection1
3CompletedTreatmentConjunctivitis, Viral1
3CompletedTreatmentExfoliation Syndrome / Glaucoma, Primary Open Angle (POAG)1
3CompletedTreatmentEye Dryness2
3CompletedTreatmentHepatitis C Viral Infection1
3CompletedTreatmentLeukemias2
3CompletedTreatmentBacterial blepharitis / Xerophthalmia1
3Not Yet RecruitingTreatmentCritical Illness / Occasional Constipation1
3TerminatedTreatmentChronic Hepatitis C Virus (HCV) Infection1
3Unknown StatusTreatmentAdenovirus / Conjunctivitis1
4Active Not RecruitingOtherColorectal Polyps1
4Active Not RecruitingTreatmentPatients Undergoing Elective Colonoscopy1
4CompletedNot AvailableColonoscopy1
4CompletedNot AvailableEndothelial Graft Rejection1
4CompletedNot AvailableEye Dryness2
4CompletedNot AvailableMyopia1
4CompletedBasic ScienceEye Dryness1
4CompletedOtherChronic Constipation1
4CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
4CompletedTreatmentColonoscopy Preparation1
4CompletedTreatmentColorectal Cancers1
4CompletedTreatmentConjunctivitis, Seasonal Allergic2
4CompletedTreatmentDiabetic Macular Edema (DME)1
4CompletedTreatmentDry Eye Syndrome (DES)1
4CompletedTreatmentDry Eye Syndromes2
4CompletedTreatmentDry Eye Syndromes / Eye Dryness1
4CompletedTreatmentEye Dryness3
4CompletedTreatmentGlaucoma1
4CompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension1
4CompletedTreatmentOccasional Constipation1
4CompletedTreatmentOpen-angle Glaucoma (OAG)1
4RecruitingDiagnosticBowel preparation therapy1
4RecruitingPreventionSurgery, Colorectal1
4RecruitingTreatmentDry Eye Syndrome (DES)1
4RecruitingTreatmentOccasional Constipation / Peritoneal dialysis complication1
4TerminatedDiagnosticColonoscopy Failure / Poor Bowel Preparation1
4Unknown StatusDiagnosticEye Dryness1
4Unknown StatusTreatmentBowel Preparation for Colonoscopy1
4Unknown StatusTreatmentEye Dryness1
4WithdrawnTreatmentDry Eye Syndrome (DES)1
Not AvailableCompletedNot AvailableChronic Hepatitis C Virus (HCV) Infection / Genotype 1 / HCV-11
Not AvailableCompletedNot AvailableColonoscopy Preparation1
Not AvailableCompletedNot AvailableEffectiveness of SMS to Fix PC Interval1
Not AvailableCompletedDiagnosticCancer Colon / Colorectal Polyps / Inflammatory Bowel Diseases (IBD)1
Not AvailableCompletedDiagnosticColorectal Cancer Screening1
Not AvailableCompletedPreventionCataracts1
Not AvailableCompletedPreventionEye Dryness1
Not AvailableCompletedSupportive CareBowel Cleansing Quality / Colonoscopy1
Not AvailableCompletedSupportive CarePain NOS2
Not AvailableCompletedTreatmentDry Eye Syndrome (DES)4
Not AvailableCompletedTreatmentEye Dryness1
Not AvailableCompletedTreatmentGlaucoma1
Not AvailableCompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Pseudoexfoliation Syndrome1
Not AvailableCompletedTreatmentIntraocular Pressure1
Not AvailableCompletedTreatmentKeratoconjunctivitis Sicca1
Not AvailableCompletedTreatmentMigraines1
Not AvailableNot Yet RecruitingNot AvailableBowel preparation therapy1
Not AvailableNot Yet RecruitingTreatmentColonoscopy1
Not AvailableRecruitingHealth Services ResearchAcute Kidney Injury (AKI)1
Not AvailableRecruitingSupportive CarePain NOS1
Not AvailableRecruitingTreatmentAdenoviral Conjunctivitis / Conjunctivitis1
Not AvailableUnknown StatusTreatmentChronic Hepatitis C Virus (HCV) Infection1
Not AvailableUnknown StatusTreatmentHepatitis C Viral Infection1
Not AvailableWithdrawnScreeningPatients Undergoing Screening or Surveillance Colonoscopy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidOphthalmic
Solution / dropsOphthalmic2.5 mg/1mL
SolutionOphthalmic
CreamTopical.3 mg/15mg
Solution / dropsIntraocular
Solution, gel forming / dropsOphthalmic
CreamTopical2.5 mg/50mg
CreamTopical
GelOphthalmic
Kit
Solution / dropsOphthalmic
LiquidOphthalmic1 %
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
boiling point (°C)>250MSDS
water solubility100 % solubleMSDS
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Zinc ion binding
Specific Function
By generating PPi, plays a role in regulating pyrophosphate levels, and functions in bone mineralization and soft tissue calcification. PPi inhibits mineralization by binding to nascent hydroxyapat...
Gene Name
ENPP1
Uniprot ID
P22413
Uniprot Name
Ectonucleotide pyrophosphatase/phosphodiesterase family member 1
Molecular Weight
104923.58 Da
References
  1. Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex vivo and Distribution in vivo [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Leukotriene-b4 20-monooxygenase activity
Specific Function
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 2...
Gene Name
CYP4A11
Uniprot ID
Q02928
Uniprot Name
Cytochrome P450 4A11
Molecular Weight
59347.31 Da
References
  1. PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Zinc ion binding
Specific Function
Class-III ADH is remarkably ineffective in oxidizing ethanol, but it readily catalyzes the oxidation of long-chain primary alcohols and the oxidation of S-(hydroxymethyl) glutathione.
Gene Name
ADH5
Uniprot ID
P11766
Uniprot Name
Alcohol dehydrogenase class-3
Molecular Weight
39723.945 Da
References
  1. PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sulfotransferase activity
Specific Function
Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of catecholamines, phenolic drugs and neurotransmitters. Has also estroge...
Gene Name
SULT1A1
Uniprot ID
P50225
Uniprot Name
Sulfotransferase 1A1
Molecular Weight
34165.13 Da
References
  1. PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies [Link]

Drug created on December 03, 2015 09:51 / Updated on November 16, 2018 11:28